TI
ATRA icon

Trexquant Investment’s Atara Biotherapeutics ATRA Stock Holding History

Trexquant Investment’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,262
Closed -$293K – 1512
2022
Q1 		$293K Buy
1,262
+723
+134% +$230K 0.01% 1021
2021
Q4 		$212K Sell
539
-551
-51% -$232K 0.01% 1119
2021
Q3 		$488K Buy
+1,090
New +$391K 0.04% 549
2021
Q2 		– Sell
-928
Closed -$333K – 1086
2021
Q1 		$333K Sell
928
-371
-29% -$164K 0.03% 694
2020
Q4 		$637K Sell
1,299
-1,193
-48% -$551K 0.07% 370
2020
Q3 		$807K Buy
2,492
+1,925
+340% +$656K 0.05% 493
2020
Q2 		$206K Sell
567
-81
-13% -$20.5K 0.01% 1038
2020
Q1 		$138K Buy
+648
New +$206K 0.01% 1019
2019
Q3 		– Sell
-596
Closed -$300K – 853
2019
Q2 		$300K Buy
+596
New +$421K 0.03% 600
2018
Q2 		– Sell
-646
Closed -$629K – 895
2018
Q1 		$629K Buy
+646
New +$589K 0.04% 559

Other funds holding ATRA

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Trexquant Investment's ATRA Position: Q2 2022 in Review

Trexquant Investment sold out of Atara Biotherapeutics (ATRA) in Q2 2022, closing a stake of 1,262 shares — an estimated $293K sold.

Trexquant Investment first reported a position in ATRA in Q1 2018 and held it in 10 quarters. The position peaked at $807K in Q3 2020. 134 funds tracked by Wall St. Rank hold ATRA as of Q2 2022.

  • Trexquant Investment reported no remaining Atara Biotherapeutics position as of Q2 2022 after selling out during the quarter.
  • Trexquant Investment sold 1,262 Atara Biotherapeutics shares in Q2 2022, an estimated $293K.
  • Trexquant Investment first reported a position in Atara Biotherapeutics in Q1 2018 and held it in 10 quarters.
  • Trexquant Investment's Atara Biotherapeutics position peaked at $807K in Q3 2020.
  • 134 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2022.

Based on Trexquant Investment's 13F filing for Q2 2022, filed 11 Aug 2022.